{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T22:23:39Z","timestamp":1785018219326,"version":"3.55.0"},"reference-count":25,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T00:00:00Z","timestamp":1749600000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>Hemophagocytic lymphohistiocytosis (HLH) is a life-threatening hyper-inflammatory clinical syndrome characterized by a storm of inflammatory factors. In the treatment of HLH, it is critical to provide active and effective treatment immediately and hamper the inflammatory cytokine storm in a timely manner to improve patient symptoms. Currently, the first-line treatment for HLH is still based on etoposide and glucocorticoids. Unfortunately, the treatment effect of HLH remains insufficient, the mortality rate of patients remains high, and the prognosis remains poor. Therefore, effective salvage treatments are urgently needed to alleviate relapsed and refractory HLH. More than 10 years have passed since the liposomal doxorubicin combined with etoposide and methylprednisolone (DEP) regimen was first reported as a salvage treatment for HLH. In more than 10 years of clinical practice, many studies have reported the effectiveness and safety of the DEP regimen for the treatment of HLH. The DEP regimen not only demonstrated a good salvage treatment effect in relapsed refractory HLH but also revealed an optimal therapeutic effect in first-line induction treatment of HLH.<\/jats:p>","DOI":"10.3389\/fphar.2025.1599873","type":"journal-article","created":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T04:10:13Z","timestamp":1749615013000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["DEP regimen for the treatment of hemophagocytic lymphohistiocytosis: a review of published experience"],"prefix":"10.3389","volume":"16","author":[{"given":"Guangqiang","family":"Meng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saran","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,6,11]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1182\/blood.2019000761","article-title":"Mechanisms of action of ruxolitinib in murine models of hemophagocytic lymphohistiocytosis","volume":"134","author":"Albeituni","year":"2019","journal-title":"Blood"},{"key":"B2","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1007\/s00277-022-04946-0","article-title":"L-DEP regimen is effective as an initial therapy for adult EBV-HLH","volume":"101","author":"Chen","year":"2022","journal-title":"Ann. Hematol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"101515","DOI":"10.1016\/j.berh.2020.101515","article-title":"Hemophagocytic lymphohistiocytosis: an update on pathogenesis, diagnosis, and therapy","volume":"34","author":"Griffin","year":"2020","journal-title":"Best. Pract. Res. Clin. Rheumatol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1007\/s00432-022-04147-2","article-title":"The emerging role of anti-PD-1 antibody-based regimens in the treatment of extranodal NK\/T-cell lymphoma-associated hemophagocytic lymphohistiocytosis","volume":"149","author":"He","year":"2023","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"B5","doi-asserted-by":"crossref","first-page":"21","DOI":"10.2147\/IJN.S1253","article-title":"Tumor targeting using liposomal antineoplastic drugs","volume":"3","author":"Huwyler","year":"2008","journal-title":"Int. J. Nanomedicine"},{"key":"B6","doi-asserted-by":"publisher","first-page":"4041","DOI":"10.1182\/blood-2011-03-278127","article-title":"How I treat hemophagocytic lymphohistiocytosis","volume":"118","author":"Jordan","year":"2011","journal-title":"Blood"},{"key":"B7","doi-asserted-by":"publisher","first-page":"2386","DOI":"10.1182\/blood.2023021046","article-title":"Differential effects of itacitinib, fedratinib, and ruxolitinib in mouse models of hemophagocytic lymphohistiocytosis","volume":"143","author":"Keenan","year":"2024","journal-title":"Blood"},{"key":"B8","doi-asserted-by":"publisher","first-page":"614704","DOI":"10.3389\/fimmu.2021.614704","article-title":"Use of the JAK inhibitor ruxolitinib in the treatment of hemophagocytic lymphohistiocytosis","volume":"12","author":"Keenan","year":"2021","journal-title":"Front. Immunol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1080\/10245332.2018.1491093","article-title":"Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis in adults and adolescents-a life-threatening disease: analysis of 133 cases from a single center","volume":"23","author":"Lai","year":"2018","journal-title":"Hematology"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.26308","article-title":"Salvage therapy for refractory hemophagocytic lymphohistiocytosis: a review of the published experience","volume":"64","author":"Marsh","year":"2017","journal-title":"Pediatr. Blood Cancer"},{"key":"B11","doi-asserted-by":"publisher","first-page":"2289","DOI":"10.1007\/s00277-022-04953-1","article-title":"Clinical characteristics and treatment of NK\/T-cell lymphoma-associated HLH","volume":"101","author":"Meng","year":"2022","journal-title":"Ann. Hematol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1080\/10428194.2020.1849671","article-title":"The DEP regimen is superior to the HLH-1994 regimen as first-line therapy for lymphoma-associated haemophagocytic lymphohistiocytosis","volume":"62","author":"Meng","year":"2021","journal-title":"Leuk. Lymphoma"},{"key":"B13","doi-asserted-by":"publisher","first-page":"3033","DOI":"10.1007\/s00432-022-04157-0","article-title":"Modified DEP regimen as induction therapy for lymphoma-associated hemophagocytic lymphohistiocytosis: a prospective, multicenter study","volume":"149","author":"Pi","year":"2023","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"507","DOI":"10.5858\/arpa.2020-0802-RA","article-title":"Hemophagocytic lymphohistiocytosis","volume":"146","author":"Ponnatt","year":"2022","journal-title":"Arch. Pathol. Lab. Med."},{"key":"B15","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1023\/a:1011080211226","article-title":"Host factors influencing the preferential localization of sterically stabilized liposomes in Klebsiella pneumoniae-infected rat lung tissue","volume":"18","author":"Schiffelers","year":"2001","journal-title":"Pharm. Res."},{"key":"B16","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s13045-016-0317-7","article-title":"PEG-aspargase and DEP regimen combination therapy for refractory Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis","volume":"9","author":"Wang","year":"2016","journal-title":"J. Hematol. Oncol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1111\/bjh.17331","article-title":"Ruxolitinib-combined doxorubicin-etoposide-methylprednisolone regimen as a salvage therapy for refractory\/relapsed haemophagocytic lymphohistiocytosis: a single-arm, multicentre, phase 2 trial","volume":"193","author":"Wang","year":"2021","journal-title":"Br. J. Haematol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"2186","DOI":"10.1182\/blood-2015-05-644914","article-title":"Multicenter study of combination DEP regimen as a salvage therapy for adult refractory hemophagocytic lymphohistiocytosis","volume":"126","author":"Wang","year":"2015","journal-title":"Blood"},{"key":"B19","first-page":"901","article-title":"Clinical study of DEP regimen as a salvage therapy for adult refractory hemophagocytic lymphohistiocytosis","volume-title":"Zhonghua Xue Ye Xue Za Zhi","author":"Wang","year":"2014"},{"key":"B20","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.3760\/cma.j.cn112137-20211224-02888","article-title":"Ruxolitinib combined with liposomal doxorubicin, etoposide, methylprednisolone+\/-PEG-asparaginase in treatment of relapsed\/refractory pediatric hemophagocytic lymphohistiocytosis","volume":"102","author":"Wei","year":"2022","journal-title":"Zhonghua Yi Xue Za Zhi"},{"key":"B21","doi-asserted-by":"publisher","first-page":"3463","DOI":"10.1007\/s00277-024-05796-8","article-title":"The effectiveness of the doxorubicin-etoposide-methylprednisolone regimen for adult HLH secondary to rheumatic disease","volume":"103","author":"Yin","year":"2024","journal-title":"Ann. Hematol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"3493","DOI":"10.1182\/blood.2021014860","article-title":"A study of ruxolitinib response-based stratified treatment for pediatric hemophagocytic lymphohistiocytosis","volume":"139","author":"Zhang","year":"2022","journal-title":"Blood"},{"key":"B23","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1111\/bjh.16861","article-title":"L-DEP regimen salvage therapy for paediatric patients with refractory Epstein-Barr virus-associated haemophagocytic lymphohistiocytosis","volume":"191","author":"Zhao","year":"2020","journal-title":"Br. J. Haematol."},{"key":"B24","article-title":"Ruxolitinib combined with dexamethasone for adult patients with newly diagnosed hemophagocytic lymphohistiocytosis in China","volume-title":"Blood","author":"Zhou","year":"2025"},{"key":"B25","doi-asserted-by":"publisher","first-page":"8521","DOI":"10.1007\/s00432-023-04781-4","article-title":"Serum sCD25\/ferritin ratio combined with MCP-1 is a valid predictor for identifying LAHS with HLH as the first manifestation","volume":"149","author":"Zou","year":"2023","journal-title":"J. Cancer Res. Clin. Oncol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1599873\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T04:10:15Z","timestamp":1749615015000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1599873\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,11]]},"references-count":25,"alternative-id":["10.3389\/fphar.2025.1599873"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1599873","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,11]]},"article-number":"1599873"}}